Moderna to present late-breaking Phase 3 melanoma data for intismeran autogene at ESMO 2026

By Public Technologies
  • Moderna flagged three ESMO Congress 2026 presentations on intismeran autogene, an individualized mRNA neoantigen therapy developed with Merck.
  • Late-breaking Phase 3 melanoma data are scheduled for Oct. 24, 2026, signaling an upcoming readout for a pivotal adjuvant program.
  • Earlier-stage updates in pancreatic cancer and early-stage NSCLC are also slated for poster sessions, extending the product’s potential across multiple tumors.
  • Results have not yet been presented; disclosures are planned for Oct. 23-27, 2026, in Madrid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609211012ACCESSWRNAPR_____1224628) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.